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Objectives. We attempted to determine whether the coronary 
vasomotor response to exercise improves after cholesterol- 
lowering drug therapy with bezafibrate. 
Background. Hypercholesterolemia and other coronary risk 
factors are associated with impaired endothelium-dependent cor- 
onary vasomotor response to physiologic or pharmacologic stimuli, 
even in the absence of overt coronary atherosclerosis. It is still 
unknown whether the coronary artery vasomotor esponse to dy- 
namic exercise improves under cholesterol-lowering drug therapy. 
Methods. Of 15 male patients (age 51 -+ 7 years [mean -+ SD]) 
included in the study, 7 had markedly elevated cholesterol levels 
(>6.5 mmol/liter, therapy group), and 8 had normal or slightly 
elevated cholesterol evels (<6.5 mmol/liter, control group). At 
baseline and after 7 months of cholesterol.lowering therapy with 
bezafibrate (400 rag/day) in the therapy group, coronary vasomo- 
tor response to dynamic exercise (percent change in cross- 
sectional vascular area at maximal exercise vs. rest [100%]) in 
normal and stenotic, previously dilated vessels was assessed by 
quantitative coronary angiography. 
Results. During follow-up, total serum cholesterol levels in the 
therapy group decreased from 7.8 -+ 1.1 to 5.8 + 1.1 retool/liter 
(p = 0.0001) and did not change significantly in the control group 
(from 5.4 -+ 0.9 to 6.0 -+ 1.2 retool/liter, p = NS). Exercise.induced 
vasomotor esponse (at similar work loads in the therapy and 
control groups) in both normal and dilated stenotic coronary 
arteries improved significantly in the therapy group, from 100 -+ 
9% to 109 - 7% (p = 0.0001, cross-sectional rea at rest 100%) 
and from 80 -+ 11% to 106 + 7% (p = 0.0002), respectively, but did 
not improve during follow-up in the control group. 
Conclusions. The present study indicates that cholesterol- 
lowering drug therapy with bezafibrate for 7 months improves 
exercise.induced vasomotion of angiographically normal coronary 
arteries. Seven months after coronary angioplasty, the reduction 
in serum cholesterol levels is, at least in part, associated with a 
restoration of the initially disturbed vasomotor esponse of ste. 
notic vessel segments to exercise. 
(JAm Coil Cardiol 1995;26:1615-22) 
Coronary artery disease is anatomically characterized by ath- 
erosclerotic plaques, leading to lumen irregularities or segmen- 
tal stenoses, and functionally characterized by a loss of the 
vasodilatory response to increased blood flow (induced by 
exercise or papaverine), acetylcholine or other vasoactive 
substances (e.g., serotonin, norepinephrine, adenosine, vaso- 
pressin) (1-6). In the presence of hypercholesterolemia and 
other coronary risk factors, alterations of the vasodilatory re- 
sponse may be evident even before structural coronary athero- 
sclerotic hanges are detected (7-9). Later in the development of
coronary atherosclerosis, vasoactive substances such as acetylcho- 
line and physiologic stimuli have been shown (7,8,10-12) to 
cause either vascular dilation or constriction, depending on 
whether normal or stenotic vessel segments are investigated. 
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There have been few studies in humans suggesting that 
lowering serum cholesterol levels improves the acetylcholine- 
induced endothelium-dependent vasomotor response in nor- 
mal coronary arteries (13-16). However, it is not known 
whether serum cholesterol reduction leads to an enhanced 
vasomotor response to a more physiologic stimulus: dynamic 
physical exercise. It is also not known whether the observed 
restoration of the vasomotor esponse in stenotic segments 
after coronary angioplasty (17) is influenced by a reduction in 
serum cholesterol levels. 
Therefore, the purpose of the present study was to deter- 
mine whether educing elevated serum cholesterol levels with 
bezafibrate (through decreased activity of hepatic cholesterol 
7-alpha-hydroxylase [18]) is associated with an improvement in 
exercise-induced coronary artery vasomotion of angiographi- 
cally normal and dilated stenotic vessel segments. 
Methods  
Study patients. Fifteen male patients (age 51 _+ 7 years 
[mean _+ SD]), were included in the present, retrospective 
analysis; all 15 have been described elsewhere (12,17). In the 
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study by Suter et al. (17), exercise-induced coronary vasomo- 
tion was investigated irrespective of the presence or absence of 
hypercholesterolemia or other coronary risk factors. Of 31 
patients undergoing percutaneous transluminal coronary an- 
gioplasty, 21 (-67%) had restoration of exercise-induced 
coronary vasomotion of the previously stenotic vessel segment 
by 6 months after coronary angioplasty. In 61 patients, includ- 
ing the 15 patients in the present investigation (selected for 
coronary angioplasty), an association between serum choles- 
terol evels, as well as other coronary risk factors, and exercise- 
induced coronary vasomotor response of angiographically nor- 
mal vessels was found (12). 
Seven patients with severe hypercholesterolemia (serum 
cholesterol level ->6.5 mmol/liter) and eight control patients 
(serum cholesterol <6.5 mmol/liter) who had one- or two- 
vessel coronary artery disease (one or more stenotic lesions 
>50% in diameter) were enrolled in the present study. All 
patients underwent coronary angioplasty for effort angina 
pectoris. Five patients had had a previous myocardial infarc- 
tion. All 15 patients performed upright bicycle exercise testing 
the day before coronary arteriography, and ST segment de- 
pression ->0.1 mV was found in 10 (mean 0.13 _+ 0.11 mV). 
In each patient, one vessel free of any stenotic lesions or 
lumenal irregularities was compared with the stenotic vessel 
segment destined for coronary angioplasty. Before enrollment 
in the study, no patient had received cholesterol-lowering 
drugs. All patients were treated with various antianginal drugs, 
which were stopped at least 24 h before cardiac catheteriza- 
tion. Serum total and high density lipoprotein (HDL) choles- 
terol and triglyceride l vels were determined by an enzymatic 
dye method (Chol-Pap method, Boehringer, Mannheim, 
Germany) using a blood sample obtained the day before 
cardiac atheterization. Low density lipoprotein (LDL) cho- 
lesterol was calculated using the Friedewald formula (19): 
LDL cholesterol = Total cholesterol - HDL cholesterol - 
[Triglycerides/2.2]. 
After baseline study, seven patients with severely elevated 
total serum cholesterol levels (->6.5 retool/liter, therapy group) 
were assigned to receive 400 mg/day of bezafibrate (Cedur 
retard). Eight control patients with serum cholesterol levels 
<6.5 retool/liter received no cholesterol-lowering therapy 
(control group). Patients were allowed to take other antihy- 
pertensive or antianginal drugs that were not changed uring 
the follow-up period. Patients with restenosis (percent area 
stenosis ->75%) were not included in the study. 
Cardiac catheterization. Before coronary angioplasty, pa- 
tients underwent right and left heart catheterization fordiag- 
nostic purposes. Written informed consent was obtained from 
all patients. Medication was stopped at least 24 h before 
cardiac atheterization. Premedication consisted of 10 mg of 
chlordiazepoxide administered orally 1 h before the procedure. 
Aortic pressure was measured with an 8F Judkins catheter, and 
pulmonary artery pressure was determined with a 6F pacing 
catheter with a side hole for pressure measurements. Biplane 
left ventricular angiography was performed in all patients, 
followed by diagnostic oronary arteriography. 
Study protocol. The following study protocol was per- 
formed before (baseline) and 7.2 _+ 3.0 months after coronary 
angioplasty, at follow-up coronary angiography. The percuta- 
neous femoral approach was used. After diagnostic oronary 
angiography, an interval of at least 10 min was allowed for 
dissipation of the effect of the nonionic contrast medium 
(Iopamiro 370 [iopamidol 755.2 mg/ml, trometamol 1 mg/ml]) 
on coronary vasomotion. Simultaneous biplane coronary arte- 
riography was carried out in two orthogonal projections to 
guarantee optimal visualization of the stenotic lesions. A 
control arteriogram was obtained with the patient's feet at- 
tached to the bicycle ergometer (model 380 B, Siemens-Albis 
AG, Z/irich). Exercise was begun at 50 to 75 W and was 
increased every 2 rain in increments of 25 to 50 W. Coronary 
arteriography was carried out at the end of each exercise level 
with the patient holding his breath during injection of contrast 
medium. Arteriograms atmaximal exercise level were used for 
analysis of coronary vasomotion. The exercise test was termi- 
nated because of angina pectoris, fatigue or ST segment 
depression >0.2 mV. At the end of the exercise test, 1.6 mg of 
nitroglycerin was administered sublingually. Biplane coronary 
arteriography was repeated 5 min thereafter. There were no 
complications related to the study protocol. 
Quantitative coronary arteriography. Quantitative evalua- 
tion of biplane coronary arteriograms was performed with a 
semiautomatic computer system based on a film projector 
(Tagarno A/S film projector, Horsens, Denmark), a high 
resolution CCD camera (slow-scan couple device camera, 
Institute for Biomedical Engineering, Zurich, Switzerland) and 
a computer workstation (Apollo DN3000 computer worksta- 
tion, Apollo Computer AG, Wangen, Switzerland). The system 
and the methodology for computerized analysis of coronary 
arteriograms have previously been described (20,21). The 
reproducibility of lumen area measurements in coronary arte- 
riograms has been reported (20) to have an interobserver 
variability of 4.1% (standard error of the estimate, percent of 
mean vessel cross-sectional rea) and an intraobserver vari- 
ability of 2.1%. The standard error of estimate for repeated 
measurements by one observer was 0.072 mm 2 for lumen area, 
and that for interobserver variability was 0.137 mm 2 (20). 
Quantitative analysis of exercise-induced vasomotion was 
performed in a normal vessel segment of a coronary artery 
unaffected by lumen irregularities or stenoses and at the site of 
coronary angioplasty. Normal vessel measurement si es were 
selected on the basis of the following criteria: 1) sufficient 
filling of the vessel with radiographic contrast medium; 2) high 
quality end-diastolic film frame without movement artifacts; 3) 
straightness of vessel segment to be analyzed; and 4) biplane 
X-ray views fulfilling criteria 1 to 3. Angiograms were mea- 
sured in blinded manner with regard to the variables of interest 
and protocol sequence (rest or exercise or nitroglycerin) in the 
present study. Data during maximal exercise were used for 
statistical analyses and are included in tables and figures. 
Statistical analysis. Between- and within-group compari- 
sons (baseline vs. follow-up examination) of clinical, hemody- 
namic and angiographic data were performed by two-way 
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Table 1. Clinical Characteristics of 15 Male Study Patients 
Family Coronary 
Age History No. of Normal Study Angioplasty No. of Follow-Up 
Pt No. (yr) HT Smoking of CAD RF Artery Artery VD (mo) Medication 
Therapy group 
l 52 - - 2 LAD RCA 2 4.4 
2 44 + - 3 RCA LCx 1 6.8 
3 55 + 3 LAD RCA 1 9.2 
4 56 + 3 LCx LAD 1 12.0 
5 53 - + - 2 RCA LAD 2 4.2 
6 47 + 4 LAD LCx 1 9.3 
7 64 + 3 LAD LCx 2 7.6 
Mean 53 2.8 1.6 7.6 
• +SD +6 _+(I.7 _+0.5 _+2.8 
Frequency 71 f,~ 14c>k 14~ 29% (LAD), 
43% (LCx), 
28% (RCA) 
Control group 
1 56 + + - 4 RCA LCx 1 4.3 
2 46 - 1 RCA LAD 1 2.1 
3 59 2 LAD LCx 1 9.3 
4 45 + - 3 RCA LAD l 7.0 
5 61 + - + 4 LCx LAD l 1.6 
6 39 * + - 3 LAD LCx l 15.0 
7 43 + 4 LAD RCA 1 7.4 
8 46 + - 3 LAD LCx 2 6.0 
Mean 49 3.0 1.3 6.8 
_+SD -+8 - 1.1 _+0.7 +4.1 
Frequen%' 75% 63c~ 25c} 1 38% (LAD), 
50% (LCx), 
12% (RCA) 
B, N, I, A 
B, N, A, M, ASA 
B, N, I, A 
B, I, A, ASA 
B,N,  I ,D  
B, I, A, ASA 
B, N ,A ,  1 
I ,A ,C  
N, ASA 
N, I, E, F 
N , I ,A  
N , I ,A  
A 
N ,A  
N, A, ASA 
A = atenolol; ASA - aspirin; B - bezafibrate; C - coumarin; CAD = coronary, artery, disease; D - digoxin; E enalapril; F = furosemide; Hx = hypertension; 
I = isosorbide dinitrate; LAD = left anterior descending coronary artery; LCx = left circumflex coronary artery; M = molsidomine; N = nifedipine; Pt = patient; PTCA 
- coronary angioplasw; RCA right coronary' artery; RF - risk factors; VD = diseased vessels; + - yes; - = no. 
repeated measures analysis of variance (continuous variables) 
and by a chi-square test for categoric variables. Analysis of the 
effect of serum cholesterol evels and their reduction on 
exercise-induced coronary vasomotion was carried out with 
linear regression. Results are expressed as mean value _+ SD, 
and p < 0.05 was considered statistically significant. 
Resu l t s  
Clinical characteristics. Clinical characteristics (Table 1) 
were comparable in both study groups. Two patients in the 
therapy group and three in the control group had a previous 
myocardial infarction (p = NS). No patient who reported a 
smoking habit at baseline quit smoking after coronary angio- 
plasty. The number of coronary risk factors, distribution of 
stenotic vessel segments for dilation and number of vessels 
with coronary artery disease did not differ between the study 
groups. The time of follow-up varied between 2and 15 months, 
but the mean follow-up interval did not differ significantly 
between the therapy and control groups. 
Serum lipid levels. Because of the selection criteria used in 
this study, baseline total and LDL cholesterol evels were 
significantly higher in the therapy group than the control group 
(Table 2). The HDL cholesterol levels were significantly lower, 
whereas serum triglyceride levels tended to be higher, in the 
therapy than the control group. After follow-up, total and LDL 
cholesterol levels decreased significantly, and HDL cholesterol 
levels tended to be higher and triglyceride levels lower in 
patients with hypercholesterolemia, whereas these levels did 
not change significantly in control patients. 
Exercise data and hemodynamic variables. New York 
Heart Association functional class at baseline was similar in 
both groups and improved similarly after follow-up. Exercise 
work load (absolute values and percent of age-, gender- and 
height-corrected normal values) in the supine position was 
significantly lower in the therapy than control group at baseline 
but not at follow-up examination. Exercise work load improved 
to normal values in the therapy group, whereas it remained 
stable among control patients. In both groups, absolute normal 
values corresponded to -150 W. Exercise-induced angina 
pectoris occurred with similar frequency during baseline study; 
however, supine bicycle ergometry was terminated more often 
because of ST segment depression >0.2 mV on the electro- 
cardiogram in the therapy than the control group (six of seven 
vs. two of eight, p < 0.05). At follow-up, there was a tendency 
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Table 2. Serum Lipid Levels 
Total Cholesterol LDL Cholesterol 
(rnmol/liter) (retool/liter) HDL Cholesterol (mmol/liter) Tfiglycerides (mmol/liter) 
Pt No. BL FU BL FU BL/FU BL/FU BL/FU BL/FU 
Therapy group 
1 
2 
3 
4 
5 
6 
7 
Mean 
_+SD 
Control group 
1 
2 
3 
4 
5 
6 
7 
8 
Mean 
_+SD 
7.6 5.3 7.1 2.4 1.10 0.92 1.26 1.21 
8.5 7.1i 8.9 6.6 0.75 0.95 2.56 2.39 
7.5 7.2 9.9 7.8 0.87 1.00 7.33 2.82 
9.(I o.4 9.9 5.1 0.90 1.21 4.00 2.15 
6.5 4.9 6.3 3.1 0.90 1.11 2.07 1.81 
6.5 4.1 6.3 2.5 (I.95 1.06 1.65 1.80 
9.2 5.9 9.2 3,6 0.73 0.90 1.68 1.61 
7.8 5.8 8.2 4.5 0.91 1.Ol 2.9 1.97 
1.1"5. - 1.1 _+ 1.6"5 -+ 2.3 + 0.1~ = 0.11 _+ 2.1 _+ 0.54 
6.4 7.0 6.3 5.t) 1.10 1.05 2.27 2.21 
3.8 4.t~ 2.7 0.9 1.29 0.99 0.42 0.50 
4.6 3.7 3.8 1.4 1.39 1.37 1.41 1.35 
5.6 6.9 5.8 6.8 1.1)7 0.95 2.69 2.48 
6.4 6.5 6.0 5.0 1.02 1.02 1.35 2.02 
5.2 6.6 4,8 3.1 1.01 1.04 1.40 1.23 
6.4 6.7 5,7 1,7 1.06 0.94 0.79 0.65 
5.1 5.13 5.1 3.8 1.(19 1.05 1.93 1.85 
5.4 6.0 5.(! 3.6 1.11) 1.06 1.5 1.53 
0.9 ± 1.2 +_ 1.2 z2.2 +_ 0.17 _+ (I.15 _+ 0.7 +_ 0.72 
*p < 0.01 within group during follow-up. +p < 0.01 versus control group. BE = baseline; FU = follow-up; HDL = high density lipoprotein; LDL = low density 
lipoprotein; Pt = patient. 
to less frequent exercise-induced chest pain in the therapy than 
the control group. 
Maximal heart rate, mean aortic pressure and mean pul- 
monary artery pressure during exercise (Table 3) and after 
sublingual nitroglycerin administration at baseline and at 
follow-up were comparable in the two groups. Left ventricular 
ejection fraction at rest was similar in both study groups at 
baseline and at follow-up examination. 
Angiographic data. The cross-sectional areas of the normal 
epicardial coronary arteries and stenotic oronary artery seg- 
ments undergoing coronary angioplasty were similar in the 
therapy and control groups before and after follow-up: 3.8 _+ 
1.0 and 5.2 _+ 2.7 mm e, respectively, atbaseline (p = NS), and 
3.5 + 1.5 and 4.8 _+ 2.5 mm 2, respectively, at follow-up 
examination (p = NS) for normal arteries; and 0.9 +_ 0.3 and 
1.0 _+ 0.8 mm 2, respectively, atbaseline (p -- NS) and 2.7 +_ 1.1 
and 2.8 _+ 1.5 mm 2, respectively, atfollow-up examination (p = 
NS) for stenotic segments. 
Normal coronary arteries. At baseline, exercise-induced va- 
sodilation was less pronounced in severely hypercholester- 
olemic than in control patients (100 + 9% vs. 107 +_ 14~, 
respectively [vs. 100% at rest for both] p = 0.09). During 
follow-up, exercise-induced vasodilation improved significantly 
in the therapy group (to 109 _+ 7%) but remained stable in the 
control group (Fig. 1). No intergroup or intragroup differences 
in vasodilator response to nitroglycerin were seen at follow-up. 
At baseline and at follow-up examination, there was an inverse 
correlation between total serum cholesterol levels and exercise- 
induced vasodilation of angiographically normal coronary ar- 
teries in both study groups (Fig. 1). A decrease in total serum 
cholesterol levels during follow-up was significantly associated 
with an improvement in exercise-induced vasodilation of nor- 
mal vessels (Fig. 2). In the therapy group a decrease in serum 
cholesterol levels resulted in an improved vasomotor response 
in all patients, but an increase in serum cholesterol levels in the 
control group led to deteriorated vasomotor response in 50% 
of patients. 
Stenotic oronary arteries. At baseline, exercise-induced va- 
soconstriction was similar in both severely hypercholester- 
olemic and control patients (80 _ 11% vs. 79 - 14%, 
respectively [vs. 100% at rest for both], p = NS) (Fig. 3). 
During follow-up, exercised-induced vasoconstriction im- 
proved significantly in the therapy group (to 106 _+ 7%) but 
only nonsignificantly in the control group (to 100 +_ 21%, p -- 
0.08 vs. therapy group). No intergroup or intragroup differ- 
ences in vasodilator esponse to nitroglycerin between were 
seen during follow-up. 
Discuss ion  
The results of the present study indicate that cholesterol- 
lowering drug therapy with bezafibrate has a beneficial effect 
on the vasomotor response of epicardial coronary arteries to 
dynamic exercise. Several investigations (7,8,12,22) have 
shown that endothelium-dependent pharmacologically and 
physiologically induced coronary vasomotion is impaired in 
patients with coronary risk factors even in the absence of 
angiographic evidence of coronary artery disease. Recently, 
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Table 3. Exercise Data and Hemodynamic Variables 
Max Heart Rate CSA 
NYHA Work Load (%) Angina t Ex (beats/min) MAPe× (mm Hg) MPAP~x (mm Hg) EF at Rest (%) Stenosis (%) 
Pt No. (BL/FU) (BL/FU) (BL/FU) (BL/FU) (BL/FU) (BL/FU) (BL/FU) (BL/FU) 
Therapy group 
1 Ilfl 100/100 / 102/99 81/115 38/21 79/65 97/50 
2 lllflI 50/75 +/-  132/130 114,,'108 38/28 52/63 87/29 
3 I-Ilfl 102/99 - / -  120/96 147/125 52/33 74/71 86/41 
4 Ilfl 79/100 / -  117/115 85/'-- 39/-- 60/73 71/49 
5 IIlflI 76/75 +/ 84/124 81/112 31/41 47/55 88/37 
6 Ilfll 100/106 +/ 107/149 115/140 37/43 69/65 86/15 
7 II/I 50/100 - / -  79/92 134/155 35/33 69/62 80/11 
Mean --- SD 
Baseline 2.2 +- 0.6 80 ± 23+, 106 : 19 108 -+ 27 39 _+ 7 64 +- 12 85 - 8* 
Follow-up 1.4 _+ 0.5 93 + 14 115 : 22 125 ± 18 33 ± 8 65 ± 6 33 -- 16 
Frequency 43%/0% 
Control group 
1 Ilfl 107/107 +/+ 123/136 93/112 45/27 67/62 97/52 
2 II/I 102/115 - / -  126/110 120/104 39/34 65/64 93/56 
3 I1-III/II 100/100 +/+ 78/78 107/94 45/44 54/49 84/53 
4 II/II 99/99 +/ 110/93 141/131 52/39 61/71 96/50 
5 II/I 115/115 - / -  116/110 130/97 43/37 58/68 95/44 
6 If/1 101/101 / 112/120 117/118 34/42 62/60 96/24 
7 I-II/I 116/116 / 155/152 134/111 36/29 77/73 67/29 
8 II/l 100/90 +/ -  130/128 101/-- 30/-- 66/65 87/0 
Mean +- SD 
Baseline 2,0_+0.3 105+_7 119±22 118_+17 41+_7 64-7  89±10'  
Follow-up 1,3_+0.5 107±8 114+25 11(1+_20 36+_6 64_-7 39+17 
Frequency 50%/25% 
*p < 0.01 within group during follow-up. tp < 0.01 versus control group. BL : baseline; CSA cross-sectional lumen area; EF = ejection fraction; Ex = maximal 
(Max) exercise; FU = follow-up; MAP~x and MPAP~x = mean aortic and mean pulmona~ arte~ pressure at maximal exercise; NYHA = New York Heart Association 
functional class; Pt - patient; + = yes; = no. 
two uncontrolled studies (13,14) and two randomized, placebo- 
controlled investigations (15,16) in humans demonstrated that 
reducing cholesterol levels improves acetylcholine-induced 
coronary vasomotion. To our knowledge, no study has docu- 
mented that exercise, a physiologic stimulus more closely 
reflecting the daily activities of the study patients than phar- 
macologic interventions, results in an ameliorated vasomotor 
response after serum cholesterol reduction. 
Coronary vasomotion of normal vessels. The mechanism 
by which dynamic exercise normally elicits vasodilation of 
coronary arteries is probably related to both sympathetic 
stimulation and increased myocardial work, with elevated 
coronary perfusion pressure and blood flow rate. A state of 
imbalance between those physiologic factors results in a dys- 
regulation of coronary vascular tone, which is determined by 
vasoconstrictory and vasodilatory forces (23). The normal 
response to increased coronary flow has been shown (24-26) 
to depend on the integrity of endothelial function in humans 
with coronary artery disease. Accordingly, it can be assumed 
that the improved exercise-induced vasomotor esponse of 
angiographically normal epicardial coronary arteries during 
cholesterol-lowering treatment reflects an endothelium- 
dependent response. Although this response cannot be de- 
duced directly from our study, this finding is probably in keep- 
ing with that reported by others (13-16) of an acetylcholinc- 
induced, endothelium-dependent improved vasomotor e- 
sponse of normal coronary arteries after cholesterol reduction. 
However, there is a disagreement between the present study 
and several other investigations (7,8,12) and the study by 
Leung et al. (13), insofar as no association between coronary 
vasomotion and serum cholesterol level was found in the latter 
study before intervention. Why should there be a significant 
correlation between serum cholesterol levels and acetylcholine- 
induced vasomotion of angiographically normal coronary ar- 
teries after, but not before, cholesterol reduction? This may be 
explained by the recently reported data (27) of a marked 
segmental heterogeneity of coronary vasomotion of normal 
vessels in response to acetylcholine in patients with coronary 
artery disease and coronary risk factors. Flow-mediated (and 
thus exercise-induced) endothelial dysfunction has been re- 
ported (8) to occur later than acetylcholine-induced en othe- 
lial dysfunction in the process of developing atherosclerosis. 
Accordingly, and in keeping with the finding of coronary 
functional improvement preceding structural regression of 
atherosclerosis (28), it can be postulated that some tests (e.g., 
acetylcholine) for assessment of coronary endothelial dysfunc- 
tion detect improvement earlier than others (e.g., exercise). 
Possibly, dynamic exercise as a stimulus for the assessment of
the coronary functional status may be a less sensitive but more 
specific test than acetylcholine. 
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Figure 1. Top, Individual data for 
cross-sectional area change (A) in 
angiographically normal coronary 
arteries in the bezafibrate therapy 
(400 mg/day) and control groups. 
Coronary vasomotion was induced 
by dynamic exercise (Ex) and by 
1.6 mg of sublingual nitroglycerin 
(NTG). Before therapy (Baseline), 
exercise-induced coronary vasomo- 
tion was less pronounced in the 
therapy group (severe hypercholes- 
terolemia ->6.5 mmol/liter) than in 
the control group. At follow-up ex- 
amination, the vasomotor response 
to exercise was significantly im- 
proved in the therapy group but 
not in the control group. The vaso- 
motor response to nitroglycerin 
was similar in both groups at base- 
line and after follow-up. Results 
are mean value (solid symbols) +- 
SD (vertical ines). Bottom, There 
is a significant inverse correlation 
between exercise-induced coronary 
vasomotion and total serum choles- 
terol levels both at baseline xam- 
ination and after follow-up in the 
therapy and control groups. After 
follow-up, all patients in the ther- 
apy group had reduced total serum 
cholesterol evels and improved 
exercise-induced coronary vasomo- 
tion, whereas seven of eight patients 
in the control group had increased 
total serum cholesterol levels and 
overall unchanged exercise-induced 
coronary vasomotion. 
Restoration of coronary vasomotion of stenotic vessels after 
coronary angioplasty. Previous studies (11) have indicated 
that stenotic oronary artery segments constrict during exer- 
cise. Suter et al. (17) found that coronary angioplasty appears 
to have a salutary effect on coronary vasomotion of the stenotic 
segment during exercise. This effect has been shown to be 
associated in part ( -60%) with the severity of the residual 
stenosis early and late after coronary angioplasty. To our knowl- 
edge, the present study is the first to reveal that restoration of 
exercise-induced coronary vasomotion of stenoses after coronary 
angioplasty may also be related to a reduction in serum choles- 
terol levels. Five (72%) of the seven patients who showed 
exercise-induced vasodilation early after coronary angioplasty 
were in the therapy group, whereas five (63%) of eight patients 
with either no change or vasoconstriction in response to exercise 
were in the control group. Apparently, variables other than normal- 
ization of hypercholesterolemia and degree of residual stenosis at 
follow-up may determine improvement of endothelium-dependent 
dysfunction after coronary angioplasty. The extent of vascular 
injury caused by balloon inflation probably influences not only 
the prevalence of restenosis, but also restoration of vasomotor 
function after coronary angioplasty (29). 
Figure 2. There was a significant inverse correlation between the 
change in total serum cholesterol during follow-up and that in exercise- 
induced vasomotion of normal coronary arteries (AEx) in both the 
therapy (triangles, solid regression line [y = -0.8 - 5.4x, r = 0.90, p = 
0.004]) and control groups (squares, dashed regression line [y = 10.3 
- 4.5x, r = 0.82, p = 0.02]). Serum cholesterol reduction in the therapy 
group resulted in an improved vasomotor response to exercise in all 
patients, whereas erum cholesterol increase in the control group 
resulted in a deteriorated vasomotor response only with a change in 
cholesterol >1 mmol/liter. 
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Figure 3. Individual data for 
cross-sectional area change (A) in 
angiographically stenotic coro- 
nary arteries before and 7 months 
after angioplasty for patients 
in the therapy (bezafibrate, o~ 
400 mg/day) and control groups. :" 
Coronary vasomotion was in- 
duced by dynamic exercise (Ex) 
and 1.6 mg of sublingual nitro- =~ 
glycerin (NTG). Before therapy . o 
(Baseline), exercise-induced cor- 
onary vasoconstriction was simi- < 
lar in both the therapy (severe 
o hypercholesterolemia ->6.5 mmol/ 
liter) and control groups. At 
follow-up examination, the vaso- ,~ 
motor response to exercise was £ 
significantly improved in the o 
therapy group but not in the con- 
trol group. The vasomotor e- 
sponse to nitroglycerin was simi- 
lar in both groups at baseline and 
after follow-up. Results are mean 
value (symbols) _+ SD (vertical 
lines). 
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Study limitations. The present study included only a small 
number of patients and was not a prospective, randomized 
trial. The control group did not receive placebo, and serum 
cholesterol levels in this group were significantly lower than 
those in the therapy group. However, age, risk factors other 
than hypercholesterolemia, severity of coronary artery disease 
and average follow-up period were comparable between the 
study groups at baseline and at follow-up examination. 
In addition to reducing total and LDL cholesterol and 
triglyceride l vels and increasing HDL cholesterol levels, beza- 
fibrate has been reported (30) to lower fibrinogen levels. 
Changes in fibrinogen, an independent risk factor for coronary, 
atherosclerosis (31), may have confounded the results of the 
present study. Fibrinogen levels were not determined in the 
present investigation. 
Clinical implications. Cholesterol-lowering therapy has 
been demonstrated byothers (32) to markedly reduce cardio- 
vascular events but with only mild regression of atherosclerotic 
stenosis. The reduction in serum cholesterol levels decreased 
symptoms of angina in such a short period of time (months) 
that regression of atherosclerosis was unlikely to occur. It is 
conceivable that the reduction of cardiovascular events is 
related to the improvement in endothelium-dependent coro- 
nary vasomotion as a result of serum cholesterol reduction 
rather than the regression of atherosclerotic stenosis itself. 
A recent study (33) showed that therapy with high dose 
lovastatin initiated before coronary angioplasty did not prevent 
or even delay the process of restenosis in the first 6 months 
after the procedure. Apart from the problem of restenosis after 
coronary angioplasty, there is that of a continued vasomotor 
dysfunction in a patent vessel, which may lead to myocardial 
ischemia under conditions of increased oxygen demand. This 
problem can, at least in part, be resolved by cholesterol- 
lowering therapy in hypercholesterolemic patients. 
Conclusions. The present study indicates that cholesterol- 
lowering therapy with bezafibrate for 6 months improves 
exercise-induced vasomotion of angiographically normal coro- 
nary arteries. Six months after coronary angioplasty, reduction 
of serum cholesterol levels is, at least in part, associated with a 
restoration of the initially disturbed vasomotor esponse of 
stenotic vessel segments to exercise. 
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